Design Therapeutics, Inc.

NasdaqGS:DSGN Voorraadrapport

Marktkapitalisatie: US$315.4m

Design Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Design Therapeutics is Pratik Shah, benoemd in Aug2023, heeft een ambtstermijn van 1.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.32M, bestaande uit 5.7% salaris en 94.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde $ 723.67K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 4 jaar.

Belangrijke informatie

Pratik Shah

Algemeen directeur

US$6.3m

Totale compensatie

Percentage CEO-salaris5.7%
Dienstverband CEO1.3yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn3.2yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Oct 04
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Jun 19
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Mar 15
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Nov 16
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Jun 06
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Feb 09
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aug 08

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics expands board of directors

Jun 07

Design Therapeutics EPS misses by $0.24

May 10

Analyse CEO-vergoeding

Hoe is Pratik Shah's beloning veranderd ten opzichte van Design Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$48m

Jun 30 2024n/an/a

-US$51m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$361k

-US$67m

Sep 30 2023n/an/a

-US$72m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$5mUS$338k

-US$63m

Sep 30 2022n/an/a

-US$57m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021US$585kUS$310k

-US$36m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$19m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$400kUS$250k

-US$8m

Compensatie versus markt: De totale vergoeding ($USD 6.32M ) Pratik } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.24M ).

Compensatie versus inkomsten: De vergoeding van Pratik is gestegen terwijl het bedrijf verliesgevend is.


CEO

Pratik Shah (54 yo)

1.3yrs

Tenure

US$6,317,780

Compensatie

Dr. Pratik Shah, Ph D., is an Executive Chairperson at Design Therapeutics, Inc. since December 2017 and serves as its President, Chief Executive Officer and Principal Financial Officer since August 25, 20...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Pratik Shah
Co-Founder1.3yrsUS$6.32m0.23%
$ 723.7k
Sean Jeffries
Chief Operating Officer3.8yrsUS$1.28m1.44%
$ 4.5m
Aseem Ansari
Co-Founder & Scientific Advisorno datageen gegevens13.54%
$ 42.7m
Julie Burgess
Chief Accounting Officer3.2yrsgeen gegevensgeen gegevens
Mustapha Parekh
General Counselno datageen gegevensgeen gegevens
Jae Kim
Consulting Chief Medical Officer2.8yrsgeen gegevens0.0084%
$ 26.5k
Dawn Giangiulio
Controller4.6yrsgeen gegevensgeen gegevens

3.2yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DSGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Pratik Shah
Co-Founder6.9yrsUS$6.32m0.23%
$ 723.7k
Aseem Ansari
Co-Founder & Scientific Advisorno datageen gegevens13.54%
$ 42.7m
John Schmid
Independent Director4yrsUS$106.70k0.10%
$ 321.1k
Rodney Lappe
Independent Director5.3yrsUS$228.56k0.23%
$ 741.0k
Simeon George
Lead Independent Director4.8yrsUS$95.70k0%
$ 0
Deepa Prasad
Independent Director3.4yrsUS$94.20k0.042%
$ 132.6k
Heather Berger
Independent Director3.4yrsUS$94.20k0.0023%
$ 7.3k
Arsani William
Independent Director3.8yrsUS$104.20k0%
$ 0

4.0yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DSGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).